Compare

Relmada Therapeutics/$RLMD

1D1W1M3M6MYTD1Y5YMAX

About Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
Ticker
$RLMD
Sector
Health
Primary listing
NASDAQ
Employees
17
Headquarters
Coral Gables, United States
Website
www.relmada.com

RLMD Metrics

BasicAdvanced
$473M
-
-$0.85
0.49
-

What the Analysts think about RLMD

Analyst ratings (Buy, Hold, Sell) for Relmada Therapeutics stock.
Analyst projections of the future price of Relmada Therapeutics stock.

Bulls say / Bears say

In the Phase 2 study, NDV-01 produced a complete response at some point in 95% of efficacy-evaluable patients, with 76% still in response at 12 months. Relmada also reported no severe treatment-related events, supporting further testing of the bladder-cancer candidate. (Relmada Therapeutics)
The FDA has aligned with Relmada on two registrational development pathways for NDV-01, covering different NMIBC patient groups. If manufacturing and regulatory steps are completed, the programme could address more than one treatment setting. (Relmada Therapeutics)
Relmada reported $217.7 million in cash and short-term investments at the end of June, which it expects to fund operations through 2029, including the NDV-01 Phase 3 programme. That gives the company time to pursue its main clinical catalyst without an immediate funding need, based on management’s forecast. (Relmada Therapeutics)
NDV-01’s US IND and Phase 3 start moved from a mid-2026 target to an IND filing expected by year-end, as manufacturing work remains underway. This makes progress dependent on successful GMP scale-up and leaves room for further delays. (Relmada Therapeutics, Relmada Therapeutics)
The encouraging NDV-01 results come from an open-label, single-arm Phase 2 study, rather than a controlled comparison. Only 25 efficacy-evaluable patients had 12-month data, so the response rate may not predict results in larger registrational trials. (SEC)
Relmada’s March 2026 private placement issued about 29.5 million shares and included pre-funded warrants for a further 4.2 million shares. That large equity raise diluted existing holders, even though it strengthened the company’s cash position. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 20 Oct 2026.

RLMD Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

RLMD Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing RLMD

Funds
Fund name
Fund size
$RLMD weighting
SPDR Russell 2000 US Small Cap€R2US
$5B0.01%
SPDR Russell 2000 US Small Cap£R2SC
$5B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.